Journal
PHARMACOLOGY & THERAPEUTICS
Volume 195, Issue -, Pages 21-38Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pharmthera.2018.10.008
Keywords
Drug targets; Rational drug design; Essential genes; Antifungal immunotherapy; Drug discovery and development; Systemic mycoses
Categories
Funding
- Pronex-FAPDF/CNPq
- CNPq-Rede Pro-Centro-Oeste de Pesquisa
- Fundacao de Apoio a Pesquisa do Distrito Federal (FAPDF)
- Conselho Nacional de Pesquisa (CNPq)
Ask authors/readers for more resources
The need for better antifungal therapy is commonly accepted in view of the high mortality rates associated with systemic infections, the low number of available antifungal classes, their associated toxicity and the increasing number of infections caused by strains with natural or acquired resistance. The urgency to expand the range of therapeutic options for the treatment of fungal infections has led researchers in recent decades to seek alternative antifungal targets when compared to the conventional ones currently used. Although new potential targets are reported, translating the discoveries from bench to bedside is a long process and most of these drugs fail to reach the patients. In this review, we discuss the development of antifungal drugs focusing on the approach of drug repurposing and the search for novel drugs for classical targets, the most recently described gene targets for drug development, the possibilities of immunotherapy using antibodies, cytokines, therapeutic vaccines and antimicrobial peptides. (C) 2018 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available